Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GANX
GAIN THERAPEUTICS, INC.
NASDAQ
$1.77
▼ DOWN 4.32% (-0.08)

KEY STATISTICS

Market Cap$75.50 M
52w High$4.34
52w Low$1.53
Dividend Yield—
Frequency—
P/E-3.54
Volume312.03K
Shares Out.42.65M

COMPANY

LEADERSHIP

Gene Mack
CHIEF EXECUTIVE
Gene Mack

COMPENSATION 2026

Salary$500,000
Stock Awards$0
Incentive Plan Pay$150,000
All Other Comp.$14,320
Total$1,467,139

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 19, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
21

PRICE TARGET

Target High$10.00
Target Low$4.00
Target Median$8.00
Target Consensus$7.80

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$33.33K
NOV
11
WED

PRICE

$1.77 ▼ DOWN 4.32% (−$0.08)
$1.78$1.80$1.829:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.77

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com ↗

Gain Therapeutics develops therapies for diseases caused by protein misfolding, focusing on rare genetic and neurological disorders using its Site-Directed Enzyme Enhancement platform to identify small molecules that restore protein function.

INDUSTRY

Biotechnology

A PRODUCT GAIN THERAPEUTICS, INC. IS KNOWN FOR

GT-02287
GT-02287

Gain Therapeutics' lead candidate, GT-02287, an oral small molecule in clinical trials for Parkinson's, aims to restore GCase enzyme function in GBA1 mutation patients as a potential disease-modifying therapy.

COMPETITORS

COMPETITOR
DNLI COMPARE
IKT COMPARE
LLY COMPARE
PRTA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
VXF
0.00% · 480.3K
IWC
0.02% · 146.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
18.37%
HOLDERS
65
TOP 12 OF 65 · RANKED BY POSITION SIZE
Marshall Wace, Llp
1.8M sh · $3.43M
Potomac Capital Management, Inc.
1.0M sh · $3.25B
Jones Financial Companies Lllp
702.2K sh · $2.26M
Susquehanna International Group, Llp
684.3K sh · $2.2M
Greenlight Capital Inc
588.4K sh · $1.92M
Vanguard Group Inc
569.9K sh · $1.84M
Cambridge Investment Research Advisors, Inc.
568.6K sh · $1.83M
Dme Capital Management, LP
566.1K sh · $1.1M
Geode Capital Management, LLC
447.3K sh · $868.53K
Citadel Advisors LLC
373.6K sh · $661.2K
Gsa Capital Partners Llp
312.5K sh · $606K
Jane Street Group, LLC
242.3K sh · $780.3K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Riley Jeffrey Scott
Purchase · 25.0K shares
2026-07-15
★
DIRECTOR
HASLER HANS PETER
Purchase · 25.0K shares
2026-07-15
★
DIRECTOR
GOLDSTEIN DOV A MD
Purchase · 25.0K shares
2026-07-15
★
DIRECTOR
Nicaise Claude
Purchase · 25.0K shares
2026-07-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
BTIG BUY HC Wainwright & Co. BUY Maxim Group BUY

SECTORS PEERS

PEERPRICE
ADAG$3.68COMPARE
FBIO$2.77COMPARE
ACET$9.06COMPARE
OSTX$1.64COMPARE
XBIT$2.27COMPARE
NRXP$3.55COMPARE
NTRB$4.46COMPARE
TCRX$0.75COMPARE